The Therapeutic Goods Administration (TGA) of Australia in has approved a new treatment for relapsing forms of MS. An application for PBS listing, and this cost subsidy, has been lodged but the outcome is not yet known.
Ofatumumab (marketed as Kesimpta®) is an antibody against a protein called CD20 found on the surface of certain types of immune cells called B cells. It is similar to the already approved MS medication ocrelizumab (Ocrevus), which also targets cells with CD20 protein on their surface.
One novel feature of ofatumumab is that this treatment is given once per month, via self-injection using a special injector known as a Sensoready Pen (a patient-friendly autoinjector pen).
The American Food and Drug Administration (FDA) approved ofatumumab in mid- 2020 for the treatment of relapsing MS, which includes clinically isolated syndrome (CIS), relapsing-remitting MS, and active secondary progressive MS.
The approval of ofatumumab in Australia means that there are now 15 disease modifying therapies approved in Australia for MS, the majority for relapsing MS.
As no two people experience MS in the same way, it is important to discuss any potential treatments with their neurologist.
For more information head to MSA’s website.